School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, China.
CAS Key Laboratory of Receptor Research and State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Angew Chem Int Ed Engl. 2022 Dec 23;61(52):e202212378. doi: 10.1002/anie.202212378. Epub 2022 Nov 28.
The coronavirus papain-like protease (PL ) plays an important role in the proteolytic processing of viral polyproteins and the dysregulation of the host immune response, providing a promising therapeutic target. However, the development of inhibitors against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PL is challenging owing to the restricted S1/S2 sites in the substrate binding pocket. Here we report the discovery of two activators of SARS-CoV-2 PL and the identification of the unique residue, cysteine 270 (C270), as an allosteric and covalent regulatory site for the activators. This site is also specifically modified by glutathione, resulting in protease activation. Furthermore, a compound was found to allosterically inhibit the protease activity by covalent binding to C270. Together, these results elucidate an unrevealed molecular mechanism for allosteric modulation of SARS-CoV-2 PL and provid a novel site for allosteric inhibitors design.
冠状病毒木瓜蛋白酶样蛋白酶 (PL) 在病毒多蛋白的蛋白水解加工和宿主免疫反应失调中发挥重要作用,是一个很有前途的治疗靶点。然而,由于底物结合口袋中的 S1/S2 位点受限,针对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) PL 的抑制剂的开发具有挑战性。在这里,我们报告了两种 SARS-CoV-2 PL 激活剂的发现,并确定了独特的残基半胱氨酸 270 (C270) 作为激活剂的别构和共价调节位点。该位点还被谷胱甘肽特异性修饰,导致蛋白酶激活。此外,还发现一种化合物通过与 C270 的共价结合来别构抑制蛋白酶活性。总之,这些结果阐明了 SARS-CoV-2 PL 别构调节的未被揭示的分子机制,并为别构抑制剂的设计提供了一个新的位点。